308 related articles for article (PubMed ID: 24996555)
1. Future of polypill use for the prevention of cardiovascular disease and strokes.
Chrysant SG; Chrysant GS
Am J Cardiol; 2014 Aug; 114(4):641-5. PubMed ID: 24996555
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension.
Chrysant SG; Chrysant GS
Curr Hypertens Rep; 2016 Feb; 18(2):14. PubMed ID: 26781254
[TBL] [Abstract][Full Text] [Related]
3. Polypill: quo vadis?
Muscente F; De Caterina R
J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
[TBL] [Abstract][Full Text] [Related]
4. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
5. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
6. The polypill: a potential global solution to cardiovascular disease.
Nguyen C; Cheng-Lai A
Cardiol Rev; 2013; 21(1):49-54. PubMed ID: 23018668
[TBL] [Abstract][Full Text] [Related]
7. The polypill in the primary prevention of cardiovascular disease.
Wald DS; Wald NJ
Fundam Clin Pharmacol; 2010 Feb; 24(1):29-35. PubMed ID: 20002198
[TBL] [Abstract][Full Text] [Related]
8. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
[TBL] [Abstract][Full Text] [Related]
9. Polypill strategy for primary prevention of cardiovascular disorders.
Dabhadkar KC; Bellam N
Drugs Today (Barc); 2013 May; 49(5):317-24. PubMed ID: 23724411
[TBL] [Abstract][Full Text] [Related]
10. The challenge of polypharmacy in cardiovascular medicine.
Volpe M; Chin D; Paneni F
Fundam Clin Pharmacol; 2010 Feb; 24(1):9-17. PubMed ID: 19817871
[TBL] [Abstract][Full Text] [Related]
11. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
12. Polypills for the prevention of Cardiovascular diseases.
Kolte D; Aronow WS; Banach M
Expert Opin Investig Drugs; 2016 Nov; 25(11):1255-1264. PubMed ID: 27645895
[TBL] [Abstract][Full Text] [Related]
13. The cardiovascular polypill in high-risk patients.
Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
[TBL] [Abstract][Full Text] [Related]
14. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
[TBL] [Abstract][Full Text] [Related]
15. A polypill strategy to improve adherence: results from the FOCUS project.
Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
[TBL] [Abstract][Full Text] [Related]
16. Polypill and global cardiovascular health strategies.
Sanz G; Fuster V
Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
[TBL] [Abstract][Full Text] [Related]
17. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
[TBL] [Abstract][Full Text] [Related]
18. Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease.
Selak V; Bullen C; Stepien S; Arroll B; Bots M; Bramley D; Cass A; Grobbee D; Hillis GS; Molanus B; Neal B; Patel A; Rafter N; Rodgers A; Thom S; Tonkin A; Usherwood T; Wadham A; Webster R
Eur J Prev Cardiol; 2016 Sep; 23(13):1393-400. PubMed ID: 26945024
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacologic prevention of cardiovascular diseases--2005].
Kancz S
Orv Hetil; 2005 May; 146(20 Suppl 2):1122-31. PubMed ID: 15945241
[TBL] [Abstract][Full Text] [Related]
20. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
